Prognosis of 51 patients with primary malignant melanomas of the cervix and vagina

杨莉; 吴小华; 张志毅; 李子庭; 王华英; 臧荣余; 程玺

doi:10.3969/j.issn.1007-3969.2013.07.011

您当前的位置：

首页 >

文章列表页 >

Prognosis of 51 patients with primary malignant melanomas of the cervix and vagina

更新时间：2025-12-31

- Prognosis of 51 patients with primary malignant melanomas of the cervix and vagina
- China Oncology Vol. 23, Issue 7, Pages: 540-546(2013)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.07.011
  CLC：
- Published Online：03 March 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
杨莉,吴小华,张志毅,李子庭,王华英,臧荣余,程玺. 原发性宫颈及阴道恶性黑色素瘤51例的临床分析[J]. 中国癌症杂志, 2013, 23(7): 540-546.

杨莉, 吴小华, 张志毅, et al. Prognosis of 51 patients with primary malignant melanomas of the cervix and vagina[J]. China Oncology, 2013, 23(7): 540-546.
杨莉,吴小华,张志毅,李子庭,王华英,臧荣余,程玺. 原发性宫颈及阴道恶性黑色素瘤51例的临床分析[J]. 中国癌症杂志, 2013, 23(7): 540-546. DOI： 10.3969/j.issn.1007-3969.2013.07.011.

杨莉, 吴小华, 张志毅, et al. Prognosis of 51 patients with primary malignant melanomas of the cervix and vagina[J]. China Oncology, 2013, 23(7): 540-546. DOI： 10.3969/j.issn.1007-3969.2013.07.011.

摘要

背景与目的：原发性宫颈及阴道恶性黑色素瘤是一类罕见的、恶性程度高、预后极差的肿瘤。本研究旨在探讨原发性宫颈及阴道恶性黑色素瘤患者的临床特点、治疗方式及预后。方法：对复旦大学附属肿瘤医院1998年12月—2011年7月收治的51例宫颈及阴道恶性黑色素瘤患者的临床资料进行回顾性分析。结果：2、4年无进展生存率分别为32.8%、13.1%，2、4年总生存率分别为67.2%、39.8%，3例带瘤生存超过5年。随访期内，29例(56.9%)患者发生复发转移，主要部位为阴道残端/盆腔(10例，34.5%)、肝(4例，13.9%)、肺(3例，10.3%)、骨(3例，10.3%)和外阴(3例，10.3%)等。单因素分析显示，肿瘤大小和脉管癌栓是影响患者总体生存的重要因素(P＜0.05)，盆腔淋巴结转移是影响无进展生存的重要因素(P＝0.05)。术后联合放化疗和免疫治疗组中位疾病进展时间为17个月，而单纯化疗组为9个月，单纯免疫治疗组为11个月。结论：原发性宫颈及阴道恶性黑色素瘤预后差。手术、放化疗和免疫综合治疗具有控制疾病进展、延长患者生存的作用。

Abstract

Background and purpose: Primary malignant melanomas of the uterine cervix and vagina are rare neoplasms with very poor prognosis. This article aimed at investigating the clinicopathologic characteristics

treatment and prognosis of primary malignant melanomas of the cervix and vagina. Methods: The clinical data of 51 patients with primary malignant melanomas of the cervix and vagina treated at Fudan University Shanghai Cancer Center from Dec.1998 to Jul. 2011 were reviewed. Results: The 2- and 4-year progression-free survival (PFS) rates were 32.8% and 13.1%

respectively. The 2- and 4-year overall survival (OS) rates were 67.2% and 39.8%

respectively. Three patients survived more than 5 years. Twenty-nine (56.9%) patients had a recurrence. The common sites were vaginal stump/pelvis (10 patients

34.5%)

liver (4 patients

13.9%)

lung (3 patients

10.3%)

bone (3 patients

10.3%) and vulva (3 patients

10.3%). Larger tumor size and lymphovascular space invasion were the independent predictors of poor OS (P0.05). Pelvic lymph nodes metastases were associated with shorter PFS (P=0.05). Among them

those who received combined immunotherapy and chemoradiotherapy achieved longer median time to progression (TTP) (17 months) compared with patients who had chemotherapy alone (9 months) or immunotherapy alone (11 months). Conclusion: Primary melanomas of cervix and vagina have a very poor prognosis. The multidisciplinary treatment of combining surgery

chemoradiotherapy

and immunotherapy can improve the patients’ prognosis.

关键词

Keywords

references

Views

2824

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Advance in current management of patients with anaplastic thyroid carcinoma

Impact of radiation-induced lymphopenia on prognosis in patients with limited-stage small cell lung cancer: a cohort study

Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer

The progress of treatment for brain metastases of triple-negative breast cancer

Related Author

Sumei FAN

Congling XIN

Laifang ZHU

Chang LIU

Rui XU

Zhengrong ZHOU

Xi CHENG

陈静

Related Institution

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰